INTRODUCTION
It is a textbook knowledge that botulinum toxin type A (BTX-A) in botulism, as well as in therapeutic applications, exerts the neuromuscular paralysis by enzymatic cleavage of peripheral synaptosomal-associated protein 25 (SNAP-25), involved in neuroexocytosis. Unlike related tetanus toxin, which is known to be retrogradely transported and transcytosed to second-order synapses (Schwab et al., 1979) , it was generally accepted that BTX-A acts directly only on peripheral nerve endings. Nevertheless, already in the 70-ties some authors reported axonal transport of radioactively labeled botulinum toxin A (BTX-A) within peripheral nerves to spinal cord (Habermann, 1974; Wiegand et al., 1976) . Those observations remained forgotten and questioned in later studies (Tang Liu et al., 2003) . Main objections to these early studies were that it was not known if radioactively labeled BTX-A retained the enzymatic activity by the time it reached spinal cord. However, axonal transport of functional BTX-A molecules was recently found in hippocampus, visual system and in facial motoneurons (Antonucci et al., 2008) . BTX-A axonal transport followed by enzymatic cleavage in CNS has been demonstrated in trigeminal sensory neurons (Matak et al., 2011) . Recent in vitro study suggests spread of BTX-A within cell bodies and distal processes of cultured sympathetic neurons (Lawrence et al., 2011) .
Retrograde axonal transport of low dose BTX-A in spinal sensory neurons has been suggested by behavioral experiments in models of bilateral muscular hyperalgesia (Bach-Rojecky & Lacković, 2009 ) and diabetic neuropathy (Bach-Rojecky et al., 2010) .
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In present study we found the enzymatic activity of BTX-A in rat motor and sensory regions of the spinal cord after intramuscular, subcutaneous, or intraneural toxin application.
MATERIALS & METHODS

Animals
18 male Wistar rats (University of Zagreb School of Medicine, Croatia), weighing 300-400 g, kept on 12 h/12h light and dark cycle with unlimited access to food and water, 3 months old, were used. Experiments were conducted according to the European Communities Council Directive (86/609/EEC). Animal procedures were approved by the Ethical Committee of University of Zagreb, School of Medicine (permit No. 07-76/2005-43) . All efforts were made to reduce the suffering of animals and the number of animals used. 5 U/kg low dose and 30 U/kg BTX-A high dose was chosen based on previous experiments (Cui et al, 2004; Bach-Rojecky et al., 2005) , and 10 U/kg dose was chosen based on preliminary data. 5 U/kg dose in humans (350 U for a 70 kg average human) is within the dose-range regularly used for treatment of spasticity (Intiso, 2012) . For i.m. and s.c. injections rats were restrained, while for the i.n. injections animals were deeply anesthetized (chloral hydrate, Sigma, St. Louis, MO, USA; 300 mg/kg intraperitoneally). Sciatic nerve was exposed after skin incision at mid-femoral level and blunt dissection through the thigh muscles. Special care was made to check for possible leakage by placing piece of parafilm under the nerve prior to i.n. injection. 0-10 µl Hamilton needle (Hamilton, Bonaduz, Switzerland) was used to inject saline/colchicine and BTX-A into the nerves. 3 minutes following the treatment, parafilm was removed, the nerve returned to previous position and the skin sutured. After the operation animals were left to recover from anesthesia under warm bulb light and returned to their cages.
Experimental procedure
Immunohistochemistry
Animal preparation and immunohistochemistry was performed similarly as previously described (Matak et al., 2011 , Antonucci et al., 2008 . In brief, 5 days after BTX-A s.c and i.m. injections or 3 days following i.n. injections, rats were deeply anesthetized with chloral hydrate and transcardially perfused with 0.9 % saline followed by fixative (4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS)). Lumbal spinal cords were removed, cryoprotected in sucrose (15% in fixative for 1 day and 30% in PBS for 2 days), and kept on -80 ºC until further use. 40 (Figures 1 and 2) . Cleaved SNAP-25 immunoreactivity was visible around motoneuronal nuclei of lamina 9 in the form of dense, small fibers, and long neuronal processes, which also extended into the lamina 7 (Figures 1 and 2) . To examine the traffic within peripheral nerves we applied BTX-A directly into the sciatic nerve.
Occurrence of truncated SNAP-25 in spinal cord after i.n. injection, preventable by proximally applied colchicine, shows that BTX-A is retrogradely transported through the peripheral nerve by means of microtubule-dependent axonal transport.
The effect of intrasciatic injection of BTX-A on pain behavior was reported before (BachRojecky and Lacković, 2009 ). How the BTX-A enters the sciatic axons is unknown. BTX-A uptake into the peripheral nerve endings is mediated by SV2C-receptor mediated endocytosis (Mahrhold et al., 2006) . If the similar mechanism exists in axons is not known. Another possibility is that BTX-A diffuses into the axoplasm through damaged axons, caused by i.n. injection itself.
In this study we found that cleaved SNAP-25 was localized in ChAT-positive cholinergic fibers surrounding the motoneuronal cell bodies. This finding indicates that, after axonal transport from periphery, botulinum toxin cleaves SNAP-25 most likely in primary motor neurons. However, the possibility that botulinum toxin, following transcytosis, enters cholinergic nerve terminals of neurons other than motoneurons cannot be ruled out completely. Novel study described the cleavage of SNAP-25 in the muscles of contralateral forelimb following peripheral BTX-A forelimb injection, thus, indicating the possibility of transcytosis within the motor neurons (Torii et al., 2011) .
In this study an indirect method of BTX-A detection (by cleaved SNAP-25 immunolabeling) was used. Antibody specificity to BTX-A-truncated and not to the intact SNAP-25 was previously confirmed by BTX-A injections into the rat hippocampus and SDS polyacrylamide gel electrophoresis followed by Western blot (Matak et al., 2011) . Single 24 kDa band corresponding to truncated SNAP-25 was visible only in BTX-A-treated animals, and position of that band was confirmed using antibody which recognizes both cleaved and intact SNAP-25. In sensory system, occurrence of truncated SNAP-25 in CNS seems to be associated with toxin's antinociceptive activity (Matak et al., 2011) . On the other hand, significance of SNAP-25 cleavage in central motor regions remains to be investigated.
Conclusion
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Appearance of truncated SNAP-25 in spinal cord following low dose i.m. BTX-A (5 U/kg) administration suggests that the axonal transport of toxin to CNS commonly occurs following peripheral administration.
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